Adial Pharmaceuticals (ADIL) Cash & Equivalents (2017 - 2026)

Adial Pharmaceuticals has reported Cash & Equivalents for 10 years, with the latest figure at $4.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 93.77% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 93.77% YoY) and the FY2025 annual result came in at $5.9 million, up 56.81% from the prior year.
• Cash & Equivalents slipped to $4.6 million in Q1 2026 per ADIL's latest filing, from $5.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $12.7 million in Q1 2022 and troughed at $315880.0 in Q3 2023.
• A 5-year average of $4.6 million and a median of $4.6 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 94.51% in 2023, then surged 1547.57% in 2024.
• Over 5 years, Cash & Equivalents stood at $4.0 million in 2022, then declined by 29.35% to $2.8 million in 2023, then jumped by 32.66% to $3.8 million in 2024, then jumped by 56.81% to $5.9 million in 2025, then fell by 22.06% to $4.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.6 million, $5.9 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.